1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genmab A/S

Genmab A/S

GNMSF
Genmab A/SUS flagOther OTC
275.00
USD
- -
- -
16.88BMarket Cap
Genmab A/S
GNMSF
(Other OTC)

Recent

price

275.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.31
1.36
1.87
2.41
2.47
2.84
4.29
6.26
7.56
12.78
25.64
19.52
31.74
36.59
48.62
59.85
62.49
Revenue per Share
-1.28
-2.32
-1.88
0.41
0.87
1.91
2.81
2.92
3.68
5.16
12.07
6.86
11.93
9.66
17.65
15.49
13.15
Basic EPS, GAAP
1.03
-1.73
0.24
-0.5
0.17
0.44
0.7
3.97
1.34
2.89
15.53
4.58
7.87
15.57
16.86
18.2
13.97
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-17.42
-19.28
-20.91
-19.26
-14.41
-10.43
-7.2
-4.75
-0.34
5.23
18.19
23.39
32.55
42.06
53
66.1
65.67
Book Value per Share
4.29
1.89
1.48
2.39
5.71
8.25
10.98
16.29
18.86
32.33
47.63
50.89
59.37
71.54
47.58
-58.42
-58
Tangible Book Value per Share
45
45
46
51
56
59
60
61
61
63
65
66
66
65
64
62
62
Basic Weighted Avg Shares
104
61
86
123
139
166
257
381
463
804
1,671
1,281
2,088
2,390
3,121
3,720
3,901
Sales/Revenue/Turnover
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.3
32.52
33.6
32.99
Operating Margin (%)
4
3
3
2
2
5
6
11
13
21
43
38
52
43
60
71
84
Depreciation Expense
-57
-104
-86
21
49
112
168
178
225
325
786
450
785
631
1,133
963
821
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
8.68
24.24
19.41
24.53
21.5
22.77
14.56
20.02
20.6
Effective Tax Rate (%)
-55.23
-169.94
-100.51
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.4
36.3
25.89
21.05
Profit Margin (%)
195
94
83
145
345
477
635
924
1,071
1,952
2,899
3,223
3,799
4,544
3,156
1,458
1,395
Working Capital
2
1
- -
- -
- -
- -
- -
- -
- -
23
46
55
75
101
131
5,135
5,058
LT Debt
193
85
68
122
332
511
683
1,011
1,228
2,106
3,160
3,379
3,927
4,687
5,137
5,847
5,682
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
17.1
17.67
31.39
10.19
18.99
13.52
16.79
11.88
12.24
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-145.47
194.21
98.81
31.82
41.24
25.11
35.85
15.47
14.53
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
103.84
33.09
42.69
25.82
36.85
25.65
21.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
16
291
293
LT Borrowings
- -
5,001
4,933
LT Finance Leases
126
134
125
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
61
Market Capitalization
123,249
125,570
107,289

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,471
2,885
2,573
Cash, Cash Equivalents & STI
3,411
1,715
1,521
Accounts Receivable, Net
1,046
1,112
968
Inventories
14
18
21
Total Current Liabilities
741
1,427
1,178
Payables & Accruals
722
1,112
861
ST Debt
16
291
293
Deferred Revenue
3
24
24

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.07%
13.18%
13.82%
Free Cash Flow
116.2%
21.84%
4.53%
Net Income, GAAP
34.56%
15.3%
-15%
Sales/Revenue/Turnover
40.99%
20.77%
19.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
603
779
816
744
3,121
2025
715
925
1,022
1,058
3,720
2026
896
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.96
3.15
2.94
- -
17.65
2025
3.06
5.44
- -
- -
15.49
2026
0.84
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
MedPacto, Inc. (235980.KQ)
Kadmon Holdings, Inc. (KDMN)
Roquefort Therapeutics plc (ROQ.L)
Kazia Therapeutics Limited (KZA.AX)
Omega Therapeutics, Inc. (OMGA)
ProMIS Neurosciences, Inc. (PMN)
Business
Genmab A/S is a biotechnology company specializing in the discovery and development of innovative antibody therapeutics for the treatment of cancer. Its core products and services include the research, development, and commercialization of antibody-based drugs; key product categories encompass immune-oncology therapies such as DARZALEX (daratumumab) — developed in collaboration with Janssen Pharmaceuticals for multiple myeloma treatment — as well as other proprietary antibody technologies and pipeline candidates focused on hematologic and solid tumors. Genmab offers a diverse portfolio of antibody therapeutics, engages in strategic partnerships with pharmaceutical companies for co-development and marketing, and provides research services based on its proprietary technology platforms. Founded in 1999, Genmab is headquartered in Copenhagen, Denmark, and operates globally through multiple collaborations and strategic alliances. Recent major developments include the expansion of its collaboration with Janssen Pharmaceuticals, including licensing new product candidates and advancing its pipeline through joint development efforts. Additionally, Genmab has enhanced its proprietary technology platforms for antibody development and engaged in new research alliances to broaden its product pipeline. These initiatives reflect a strategic focus on accelerating innovation, expanding clinical programs, and leveraging partnerships for commercial success. Genmab continues to strengthen its position in the biotechnology sector with ongoing clinical trials, new product launches, and research platform enhancements. The company serves the pharmaceutical and healthcare industries, targeting patients with cancer worldwide through its therapeutic products and joint ventures. Genmab's business segments encompass research and development, commercialization of antibody therapeutics, and collaborative partnerships. It operates across North America, Europe, and Asia through its commercial partners and maintains a robust pipeline in clinical development phases. Genmab A/S remains a leader in the biotechnology industry focusing on monoclonal antibody therapeutics with a comprehensive approach combining in-house drug development with external collaborations and strategic alliances to drive innovation and growth in oncology treatments.

Company News

APIChatGPT

  • seekingalpha.com

    Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

  • seekingalpha.com

    Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

  • seekingalpha.com

    Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) M&A Call Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

  • seekingalpha.com

    Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript

  • globenewswire.com

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

  • globenewswire.com

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

  • globenewswire.com

    Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

  • seekingalpha.com

    Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab